F
Fundacion Respirar | Departamento de Neumonologia
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Maridebart Cafraglutide
Nerandomilast
Evolocumab
Parent organization
This site is a part of Fundacion Respirar
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
2 of 3 total trials
Locations recently updated
This study is open to children and adolescents aged 2 to 17 years with interstitial lung disease (ILD). Nerandomilast has just been approved in some...
Begins enrollment in 4 months
Fibrosing Interstitial Lung Disease
Drug: Placebo
Drug: Nerandomilast
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Active, not recruiting
Obesity
Drug: Placebo
Drug: Maridebart Cafraglutide
Trial sponsors
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems